Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

130.56 +2.58 (+2.02%)
Streaming Delayed Price Updated: 11:13 AM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
29 30 Next >
Golden Cross Appears Before Incyte Investors ↗
 
Via Benzinga
News headline image
Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
From Incyte and Mirati
Via Business Wire
News headline image
Expert Ratings for Incyte ↗
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
MorphoSys' Monjuvi Shows Long-Term Durable Response In Blood Cancer Settings ↗
 
Via Benzinga
News headline image
Incyte Q2 Earnings Beat Estimates But Tightens FY22 Jakafi Sales Guidance ↗
 
Via Benzinga
News headline image
Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Incyte
Via Business Wire
News headline image
7 Cash-Rich Stocks to Buy for Peace of Mind ↗
It pays to hold cash-rich stocks that can weather any storm because of their financial strength. Investors may want to watch these seven. 
Via InvestorPlace
News headline image
2 Biotech Stocks That Could Make You Richer ↗
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors. 
Via The Motley Fool
News headline image
More than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting
From Incyte
Via Business Wire
News headline image
Recap: Incyte Q3 Earnings ↗
Incyte (NASDAQ:INCY) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Incyte missed estimated earnings by... 
Via Benzinga
News headline image
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
News headline image
Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine
From Incyte
Via Business Wire
News headline image
Analyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm' ↗
 
Via Benzinga
News headline image
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
News headline image
2 Cathie Wood Stocks That Are Beating the Market This Year ↗
One is doing much better than the other year to date, but they both have solid prospects ahead. 
Via The Motley Fool
News headline image
Incyte Names New Member to Its Board of Directors
From Incyte
Via Business Wire
News headline image
Incyte Acquires Villaris Therapeutics, Deepening Portfolio For Immune-Mediated Dermatologic Diseases ↗
 
Via Benzinga
News headline image
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody
From Incyte
Via Business Wire
News headline image
Death Cross Looms Over Incyte Investors ↗
If history is any guide, there may be trouble ahead for shares of Incyte (NASDAQ:INCY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. 
Via Benzinga
News headline image
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
Recap Of Friday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Incyte Gets FDA Nod For Hematologic Malignancies Candidate ↗
The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ: INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with... 
Via Benzinga
News headline image
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
From Incyte
Via Business Wire
News headline image
Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
10 Most Oversold Stocks To Buy In August 2022 ↗
Looking for some oversold stocks to buy? Here's the 10 most oversold on the S&P 500 for August 2022. 
Via Talk Markets
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022 ↗
  
Via Benzinga
News headline image
Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled ↗
Jakafi sales beat and the company raised its guidance. But another drug fell short. 
Via Investor's Business Daily
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.